References
- Al-Hajj M. (2007). Cancer stem cells and oncology therapeutics. Curr Opin Oncol 19: 61–64.
- Almqvist PM, Mah R, Lendahl U, and et al. (2002). Immunohistochemical detection of nestin in pediatric brain tumours. J Histochem Cytochem 50: 147–158.
- Bao S, Wu Q, McLendon RE, and et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756–760.
- Beier D, Hau P, Proescholdt M, and et al. (2007). CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010–4015.
- Bonnet D, Dick JE.. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730–737.
- Colin C, Virard I, Baeza N, and et al. (2007). Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis. Neuropathology and Applied Neurobiology 4: 431–439.
- Collins AT, Berry PA, Hyde C, and et al. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946–10951.
- Dahlstrand J, Collins VP and Lendahl U. (1992). Expression of the class VI intermediate filament nestin in human central nervous system tumours. Cancer Res 52: 5334–5341.
- Dictus C, Tronnier V, Unterberg A and Herold-Mende C. (2007). Comparative analysis of in vitro conditions for rat adult neural progenitor cells. J Neurosci Meth 161: 250–258.
- Freier K, Bosch FX, Flechtenmacher C, and et al. (2003). Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: a tissue microarray analysis. Anticancer Res 23: 3971–3977.
- Graham V, Khudyakov J, Ellis P and Pevny L.. (2003). SOX2 functions to maintain neural progenitor identity. Neuron 39: 749–765.
- Karcher S, Steiner HH, Ahmadi R, and et al. (2006). Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 118: 2182–2189.
- Liu G, Yuan X, Zeng Z, and et al. (2006). Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67.
- Ma YH, Mentlein R, Knerlich F, and et al. (2008). Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol 86: 31–45.
- Mao Y, Zhou L, Zhu W, and et al. (2007). Proliferative status of tumor stem cells may be correlated with malignancy grade of human astrocytomas. Front Biosci 12: 2252–2259.
- Neuzil J, Stantic M, Zobalova R, and et al. (2007). Tumour-initiating cells vs cancer ‘stem’ cells and CD133: what’s in the name? Biochem Biophys Res Commun 355: 855–859.
- Singh SK, Clarke ID, Terasaki M, and et al. (2003). Identification of a cancer stem cell in human brain tumours. Cancer Res 63: 5821–5828.
- Singh SK, Hawkins C, Clarke ID, et al. (2004). Identification of human brain tumour initiating cells. Nature 432: 396–401.
- Strojnik T, Røsland GV, Sakariassen PO, and et al. (2007). Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 68: 133–143.
- Vescovi AL, Galli R and Reynolds BA. (2006). Brain tumour stem cells. Nat Rev Cancer 6: 425–436.
- Veselska R, Kuglik P, Cejpek P, and et al. (2006). Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer 6:32.
- Walzlein JH, Synowitz M, Engels B, and et al. (2008). The antitumorigenic response of neural precursors depends on subventricular proliferation and age. Stem Cells 26: 2945–2954.
- Wang J, Sakariassen PØ, Tsinkalovsky O, and et al. (2008). CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122: 761–768.
- Zeppernick F, Ahmadi R, Campos B, and et al. (2008). Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14: 123–129.